Shiny Pharmaceuticals

Shiny Biopharmaceuticals is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of innovative therapies for metabolic and chronic diseases. The company's primary research efforts are directed toward high-prevalence conditions, including Type 2 Diabetes, obesity, and Non-Alcoholic Steatohepatitis (NASH). Its lead program, SY-001, is an oral small-molecule GLP-1 receptor agonist currently in Phase 2 clinical development, representing a significant advancement in patient-friendly metabolic treatments. Additionally, Shiny is advancing SY-008, a thyroid hormone receptor beta (THR-beta) agonist for NASH, and several other preclinical candidates. The company is backed by top-tier venture capital firms such as Qiming Venture Partners and TF Capital. Shiny Biopharmaceuticals aims to leverage its expertise in metabolic pathways to deliver differentiated, high-quality medicines to patients globally.